Showing 2711-2720 of 3315 results for "".
- SAV-IOL Launches Instant Focus EDOF IOL Technologyhttps://modernod.com/news/sav-iol-launches-instant-focus-edof-iol-technology/2480841/Instant Focus is a unique optical technology designed by Swiss IOL maker SAV-IOL (Swiss Advanced Vision). The technology is designed to replace the accommodative function of the eye’s natural lens after cataract surgery, and is manufactured and marketed directly from their he
- Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-announces-new-commercial-and-medicare-coverage-for-eysuvis/2480834/Kala Pharmaceuticals announced that the largest Pharmacy Benefit Manager in the United States has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 1, 2022. This adds 28.5 million people to Eysuvis coverage,
- CooperVision Seeks Proposals for 2022 Science and Technology Awardshttps://modernod.com/news/coopervision-seeks-proposals-for-2022-science-and-technology-awards/2480832/To promote continuous advancement in contact lens research and development, CooperVision is now accepting submissions for its 2022 Science and Technology Awards program. The longstanding program fosters partnerships between recipients and CooperVision scientists to explore new dimensions in visio
- Stoke Therapeutics Presents New In-Vivo Data Demonstrating Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002https://modernod.com/news/stoke-therapeutics-presents-new-in-vivo-data-demonstrating-dose-related-target-engagement-and-opa1-protein-upregulation-in-retinal-tissue-following-administration-of-stk-002/2480831/Stoke Therapeutics announced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002. Target engagement and OPA1 protein increases were sus
- Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous Anti-VEGF Wet AMD and DME Candidatehttps://modernod.com/news/ashvattha-therapeutics-presents-phase-1-safety-data-in-healthy-subjects-for-subcutaneous-anti-vegf-wet-amd-and-dme-candidate/2480829/Ashvattha Therapeutics announced the presentation of safety data from a phase 1 study of its lead candidate D-4517.2, a VEGFR/PDGFR tyrosine kinase inhibitor conjugated to a hydroxyl dendrimer, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in
- New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at ARVOhttps://modernod.com/news/new-data-on-potential-of-opus-aav-based-gene-therapies-for-rare-inherited-retinal-diseases-to-be-presented-at-arvo/2480815/Opus Genetics announced that data from two preclinical studies evaluating the potential of its gene therapies OPGx-001 and OPGx-002 to address forms of Leber congenital amaurosis (LCA) due to mutations of LCA5 or RDH12 genes, respectively, will b
- Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meetinghttps://modernod.com/news/allegro-ophthalmics-announces-new-scientific-data-to-be-presented-during-the-2022-arvo-annual-meeting/2480806/Allegro Ophthalmics announced that two scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. ARVO 2022 will be held May 1-4, 2022 in
- Apellis Announces Results from New Survey Revealing the Emotional Burden Caused by Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-results-from-new-survey-revealing-the-emotional-burden-caused-by-geographic-atrophy-ga/2480801/Apellis Pharmaceuticals announced results from a global survey conducted by The Harris Poll, which found that living with geographic atrophy (GA) can cause a substantial emotional burden and impact on independence. GA is a leading cause of blindness that affects more than 5 million people wo
- Johnson & Johnson Vision Introduces Next-Generation TearScience Activator Clear for Treatment of MGDhttps://modernod.com/news/johnson-johnson-vision-introduces-next-generation-tearscience-activator-clear-for-treatment-of-mgd/2480795/Johnson & Johnson Vision announced the availability of the next-generation TearScience Activator Clear. Building on the legacy of the TearScience LipiFlow Thermal Pulsation System—a fully automated treatment for meibomian gland dysfunction (MGD)—Johnson & Johnson Vis
- Opthea Names Quinton Oswald and Susan Orr, OD, to its Board of Directorshttps://modernod.com/news/opthea-names-quinton-oswald-and-susan-orr-od-to-its-board-of-directors/2480790/Opthea announced the appointment of Quinton Oswald and Susan Orr, OD, to its Board of Directors, effective immediately following election at a General Meeting of Shareholders on April 21st, 2022. Mr. Oswald and Dr. Orr have deep experience leading biotech companies and launching c